Navidea Biopharmaceuticals Inc

NAVB's Fundamental analysis

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

NAVB Growth rates comparisons

Navidea Biopharmaceuticals Inc 's sales fell by -98.79 % in IV. Quarter 2022 from the same quarter a year ago.

In Vitro & In Vivo Diagnostic Substances industry recorded growth of revenues by 2.08 %

Navidea Biopharmaceuticals Inc net loss deacreased by in IV. Quarter 2022 year on year, Navidea Biopharmaceuticals Inc net loss increased by -4.64 % in IV. Quarter 2022 year on year,

• More on NAVB's Growth

NAVB's Valuation comparisons

Navidea Biopharmaceuticals Inc
realized net loss in trailing twelve months.

Navidea Biopharmaceuticals Inc realized cash outflow of $ -0.07per share in trailing twelve-month period.
In Vitro & In Vivo Diagnostic Substances industry recorded net loss in trailing twelve months.

Company

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 130.72.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 338.33.

• More on NAVB's Valuation

Total Debt (Millions $)	1
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Revenue/Employee (TTM) $	-
Net Income/Employee (TTM) $	-
Receivable Turnover (TTM)	-
Tangible Book Value (Per Share $)	-0.28

NAVB's Valuation comparisons

Company

PE TTM

Industry

PE TTM

Company's Price to Sales ratio is at 130.72.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 338.33.

• More on NAVB's Valuation

• Market Capitalization (Millions $)	9
• Shares Outstanding (Millions)	33
• Employees	-
• Revenues (TTM) (Millions $)	0
• Net Income (TTM) (Millions $)	-15
• Cash Flow (TTM) (Millions $)	-2
• Capital Exp. (TTM) (Millions $)	0
• Total Debt (Millions $)	1
• Dividend TTM ($)	0 $
• Dividend Yield TTM (%)	-
• Revenue/Employee (TTM) $	-
• Net Income/Employee(TTM) $	-
• Receivable Turnover Ratio (TTM)	-
• Tangible Book Value (Per Share $)	-0.28

• Market Capitalization (Millions $)	9
• Shares Outstanding (Millions)	33
• Employees	-
• Revenues (TTM) (Millions $)	0
• Net Income (TTM) (Millions $)	-15
• Cash Flow (TTM) (Millions $)	-2
• Capital Exp. (TTM) (Millions $)	0

	*Ratio*
• Capital Ratio (MRQ)	0.32
• Total Debt to Equity (MRQ)	-
• Tangible Leverage Ratio (MRQ)	-
• Asset Turnover Ratio (TTM)	0.02
• Inventory Turnover Ratio (TTM)	0.01

NAVB's Profitability Comparisons

• More on NAVB's Key Ratios


Economy Advance Monthly Sales Consumer Price Index CPI Producer Price Index PPI Retail Inventories Personal Income Gross Domestic Product GDP Money Supply Industrial Production Productivity Employment Situation US International Trade Factory Orders Durable Goods Construction Spending Housing Starts Vehicle Unit Sales	Stocks Event Calendar EQT's Profile Stock Price EQT's Financials Business Description Fundamentals Charts & Quotes EQT's News Suppliers EQT's Competitors Customers & Markets Economic Indicators EQT's Growth Company Segments	Screening Stock Performance Growth Rates Profitability Valuation Dividend Financial Strength Efficiency Largest Companies Management Effectivness

Help

Sitemap

Advertise

About us

Glossary

Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071